Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of HLA-C*02:01:01 alleles in detection or evaluation of adverse drug reactions of efavirenz

A technology of HLA-C and alleles, applied in the field of biomedicine, to reduce the occurrence of severe drug eruption

Pending Publication Date: 2022-01-04
FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far there is no reliable test to predict the risk of drug eruption while taking efavirenz

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of HLA-C*02:01:01 alleles in detection or evaluation of adverse drug reactions of efavirenz
  • Application of HLA-C*02:01:01 alleles in detection or evaluation of adverse drug reactions of efavirenz

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 The HLA-C*01:02:01 allele is a risk allele marker for drug eruption caused by efavirenz.

[0034] 1. Sample

[0035] 1. Case samples (drug eruption group caused by efavirenz)

[0036]The case samples were 38 patients with drug eruption caused by efavirenz in Yunnan Province, China. The 38 patients received ART initial treatment for HIV / AIDs. The ratio of male to female in patients was 0.9:1, and the average age was 39 years old. The time from the start of taking EFV to the appearance of rash symptoms was 8-26 days (average 14 days). All patients stopped using efavirenz due to drug eruption caused by efavirenz, and no drug eruption occurred after stopping and changing EFV treatment. The diagnosis and classification of drug eruption are based on laboratory examination, medical history, incubation period, and the shape and distribution of rash. Drug eruptions caused by any other drug and other diseases with similar symptoms were excluded.

[0037] 2. Contro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of HLA-C*02:01:01 alleles in detection or evaluation of adverse drug reactions of efavirenz, and relates to the technical field of biological medicines. Specifically, the invention discloses application of a substance for detecting whether a person has HLA-C*02:01:01 alleles or not in preparation of a product for detecting or evaluating the risk that the person has adverse drug reactions responding to efavirenz. The invention provides marker genes, namely the HLA-C*02:01:01 alleles, which can be used for detecting or evaluating the occurrence risk of adverse drug reactions responding to efavirenz. By detecting whether the to-be-detected person carries the HLA-C*02:01:01 alleles or not, the high-risk person with efavirenz-induced drug rash can be screened; and the application is used for guiding clinical medication, so that occurrence of efavirenz-induced drug rash is reduced.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of an HLA-C*02:01:01 allele in detecting or evaluating the adverse reaction of efavirenz. Background technique [0002] Human leukocyte antigen (human leukocyte antigen, HLA) gene is located in the short arm region of human chromosome 6, 6p21.3, which is the most complex human gene system known so far. According to its arrangement on the chromosome, it can be divided into three regions: the class I gene region includes HLA-A, B, and C, and the encoded classic HLA class I molecules are expressed on the surface of all nucleated cells to recognize and present endogenous antigenic peptides , to stimulate CD8+ T cell responses. The class II gene region includes HLA-DR, DP, and DQ, and the encoded classic HLA class II molecules are mainly distributed on the surface of antigen-presenting cells and activated T cells to recognize and present exogenous antigenic peptid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6881C12Q1/6883C12N15/11
CPCC12Q1/6881C12Q1/6883C12Q2600/106C12Q2600/156
Inventor 李玉叶况轶群周晓燕
Owner FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com